

Microfluidics MF-3

Now in its third year and with the mission to grow the market for microfluidic (aka “Lab on a Chip”) enabled solutions in areas such as research, diagnostics, high throughput screening and sensing of circulating tumour cells. The MF3 consortium brings together players from all along the value chain in a trusting, confidential environment to find win-wins, engage with industry influencers such as NICE and the Patent Offices as well as funding organisations .. and do some deals along the way. Its current initiative to set standards for device interconnects as well as chip holders and key healthcare diagnostic and therapeutic applications is designed to drive down costs to end users as well as to address issues of industry fragmentation while supporting the grand vision of personalized medicine. Matching the characteristics of key markets and corporate R&D, the MF3 consortium will extend its ‘footprint’ to the USA in 2012 with a new cycle MF4 launching in Summer 2012.



“Many thanks for all your efforts in planning and delivering a really exciting programme”
- Christian Holtze BASF

Contact: peter.hewkin@cfbi.com

Inclusive Design ID-2

ID-1 launched in 2010 in Cambridge and has held meetings in Munich, Berlin and Basel, finishing up with a packed two-day meeting back in Cambridge. Members including the BBC, Roche, Nestlé, Bayer, M&S, Royal Bank of Scotland and Bosch Siemens Hausgeraete have been working together to enable the design of new mainstream products that are usable by the greatest possible proportion of the population. As populations get older this is not just a social requirement but also a major commercial growth opportunity. The group is now planning its second year, which will take the form of an Expert Practitioners’ Consortium, designated ID-10. A Steering Board is being set up to advise on programme content, which will be chaired by David Wiggins of Nestlé.



In parallel with ID-10, the high level of interest from leading companies who weren’t able to join ID-1 has led to CfBI planning another ID ‘starter’ Consortium – ID-2.

Contact rob.morland@cfbi.com

Coming Soon!

Working with its academic partners in Cambridge and beyond, CfBI is continually refining the processes which deliver member benefits within its consortia. These fall broadly into the following aspects of Open Innovation:

- Doing more with less - sharing the costs to shape and be part of a larger programme
- Collaborative advantage – achieving more as part of a group than as an individual player
- Networking to find, choose and build relationships with relevant partners.

Behind the scenes CfBI’s team are working with leading organisations to prepare new consortia on “Corporate Venturing” “New Media Industries” and “Flow Chemistry” for launch in the autumn of 2012. We are also interested in discussions about “Green Radio”, “Internet of Things”, “Personalized Medicine” and “Regenerative Medicine”.

For the latest information on our consortia, members and processes please visit www.cfbi.com or contact us on ceo@cfbi.com
++ 44 1223 850173